

2 November 2017

**Scancell Holdings Plc**  
("Scancell" or the "Company")

**Professor Lindy Durrant included in top 50 Movers and Shakers in BioBusiness 2017**

*Celebrating outstanding female leaders in UK healthcare business*

Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that Professor Lindy Durrant, Scancell's Chief Scientific Officer, has been named as one of the 50 female leaders in UK healthcare business in BioBeat's "50 Movers and Shakers in BioBusiness 2017" report.<sup>1</sup> Released annually, the report celebrates 50 outstanding women entrepreneurs and business leaders who are recognised for driving innovation in healthcare.

Professor Lindy Durrant is the co-founder and Chief Scientific Officer of Scancell. She is an internationally recognised immunologist in the field of tumour therapy. She has worked for over 20 years in translational research, developing products for clinical trials including monoclonal antibodies and cancer vaccines. Lindy and her team have developed a platform called ImmunoBody®, which uses DNA encoding human antibodies engineered to express tumour antigens, to stimulate potent killer T cells for the treatment of melanoma and lung cancer. Her team is also the first group to show that immune responses to stress induced modifications, the Moditope® platform, induces strong anti-tumour responses against breast, ovarian and bone cancers. Lindy also has a personal chair in cancer immunotherapy at the University of Nottingham and has published over 200 original papers and patents.

Professor Lindy Durrant, Chief Scientific Officer of Scancell, said:

"I am honoured to have been recognised in this report alongside some of the top business leaders in healthcare. At Scancell, we are working hard to develop products that stimulate the immune system to treat or prevent cancer recurrence. I am proud to be leading this research at an important time for the Company, as we move our lead drug candidate from the ImmunoBody® platform, SCIB1, into Phase 2 trials in the US for melanoma, and our lead product from the Moditope platform, Modi-1, into clinical trials in ovarian, triple negative breast and bone cancer."

Miranda Weston-Smith, BioBeat Founder, commented:

"Women are transforming the pace, scale and ambition of what we can do in responding to global health challenges. I am so excited to present *50 Movers and Shakers in BioBusiness 2017* – they are outstanding innovators and leaders who are giving us all a healthier world."

Nikki Yates, Senior Vice President, UK & Ireland Pharmaceuticals, GSK introduced the report and commented:

"Diversity of talent is critical to life sciences and it is great to see the contribution these women are making. *50 Movers and Shakers in BioBusiness 2017* celebrates leaders whose dedication is about innovation in the healthcare business. It is fantastic to see that these are female leaders, and that they are recognised for the progress they have made over the past year."

**Reference**

1. BioBeat. 50 Movers and Shakers in BioBusiness 2017. Available online: <http://www.mws-consulting.co.uk/news-publications/>

**For Further Information:**

Dr John Chiplin, Executive Chairman Dr Richard Goodfellow, CEO	Scancell Holdings Plc	+1 858 900 2646 +44 (0) 20 3727 1000
Freddy Crossley (Corporate Finance) Tom Salvesen (Corporate Broking)	Panmure Gordon & Co	+44 (0) 20 7886 2500
Mo Noonan/Simon Conway	FTI Consulting	+44 (0) 20 3727 1000

## **About Scancell**

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

## **About BioBeat**

BioBeat is a collaborative innovation platform for healthcare entrepreneurs and leaders, founded by Miranda Weston-Smith. BioBeat champions collaboration by bringing together scientific and business expertise, and creating a forum for investors and entrepreneurs to partner, which ultimately brings benefits to patients in the form of innovative new treatments. The publication of the 50 Movers and Shakers in BioBusiness report and a summit event – BioBeat17 – are the focus of the platform's annual activities.

Based in Cambridge, UK, BioBeat's partners are Cambridge Judge Business School's Entrepreneurship Centre and the Innovation Forum. Find out more information at <http://www.mws-consulting.co.uk/biobeat/>